2022 Updates: Lilly's Global COVID-19 Response

NOTE: For more information about Lilly's COVID-19 therapies authorized for emergency use, contact the Lilly COVID Hotline at 1-855-LillyC19 (1-855-545-5921).

• Lilly continues to closely monitor the COVID-19 pandemic and its global impact. As this is an evolving topic, Lilly will include relevant announcements and information on this page.

• If the COVID-19 pandemic has impacted your ability to afford or access your Lilly medicine, contact us via these options.

• Patients and physicians can visit the U.S. Health & Human Services (HHS) Therapeutics Distribution locator to find a potential treatment location.

Lilly has utilized the full force of its expertise to develop novel antibodies that have helped prevent hospital and death in certain individuals with COVID-19. Lilly’s purpose is to create medicines that make life better across key therapeutic areas, as well as COVID-19.  

Learn more about Lilly's past efforts to fight COVID-19.

News Releases, Resources and Multimedia

November

• Lilly's statement on FDA’s de-authorization of bebtelovimab in the U.S. (November 30)

August

• Lilly’s commercialization of bebtelovimab for COVID-19 under Emergency Use Authorization (August 8)

June

• Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options (June 29)

May

• Lilly’s statement on bebtelovimab which maintains neutralization activity against all known variants in circulation (May 18)

• FDA Approves Lilly and Incyte’s OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 (May 11)

February

• Lilly’s bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 (February 11)

• Lilly will supply up to 600,000 doses of bebtelovimab to U.S. government in ongoing effort to provide COVID-19 treatment options (February 10)

January

• Lilly's statement on the FDA's Fact Sheet update for bamlanivimab and etesevimab to include a new Limitation for Authorized Use (January 24)

• New WHO COVID-19 treatment guidelines now strongly recommend Lilly’s baricitinib for patients with severe or critical COVID-19 (January 21)